Impact of the Timing of Protective Stoma Reversal on Survival in Rectal Cancer Patients Undergoing Postoperative Adjuvant Chemotherapy: A Retrospective Single Center Study

Jiwei Wang,* Xiaoyun Lu,* Yanan Xu, Yin Wu, Tao Zhang, Jianguo Li Department of General Surgery, Digestive Disease Hospital, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, People’s Republic of China*These authors contributed equally to this workCorrespondenc...

Full description

Saved in:
Bibliographic Details
Main Authors: Wang J, Lu X, Xu Y, Wu Y, Zhang T, Li J
Format: Article
Language:English
Published: Dove Medical Press 2025-04-01
Series:Cancer Management and Research
Subjects:
Online Access:https://www.dovepress.com/impact-of-the-timing-of-protective-stoma-reversal-on-survival-in-recta-peer-reviewed-fulltext-article-CMAR
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849724773447237632
author Wang J
Lu X
Xu Y
Wu Y
Zhang T
Li J
author_facet Wang J
Lu X
Xu Y
Wu Y
Zhang T
Li J
author_sort Wang J
collection DOAJ
description Jiwei Wang,&ast; Xiaoyun Lu,&ast; Yanan Xu, Yin Wu, Tao Zhang, Jianguo Li Department of General Surgery, Digestive Disease Hospital, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Jianguo Li, Department of General Surgery, Digestive Disease Hospital, Affiliated Hospital of Zunyi Medical University, 149 Dalian Road, Huichuan District, Zunyi, Guizhou, People’s Republic of China, Tel +86-13017410630, Email jianguo_zmu@163.comBackground: Postoperative adjuvant chemotherapy used in patients with stage II/III rectal cancer, is usually administered for 3 to 6 months. However, the optimal timing of protective stoma reversal remains controversial. This study aimed to investigate the effect of stoma closure before or after adjuvant chemotherapy on survival and stoma-related complications.Methods: A retrospective analysis was conducted on 144 patients who underwent radical rectal cancer surgery, prophylactic ileostomy and adjuvant chemotherapy from June 2018 to June 2021. 104 had their stoma reversal before adjuvant chemotherapy completion (Before group) and 40 after adjuvant chemotherapy completion (After group).Results: There were no significant differences between the groups regarding demographics, clinical characteristics, perioperative complications, OS, or DFS. Pathologic T-stage [HR = 2.620 (1.291– 5.320), P = 0.008 vs HR = 2.793 (1.297– 6.017), P = 0.009] and N-stage [HR = 2.204 (1.168– 4.157), P = 0.015 vs HR = 2.068 (1.125– 3.789), P = 0.019] were identified as independent risk factors for OS and DFS. Stoma reversal after completing chemotherapy [OR = 39.979 (3.964– 403.188), P = 0.002] and comorbidity [OR = 33.395 (5.931– 188.033), P < 0.001] were independent risk factors for stoma-related complications. In high-risk stage III patients with T4 or N2, the 3-year OS rate was significantly lower in Before group than in After group (70.3% vs 92.6%, P = 0.01), as was the 3-year DFS rate (60.94% vs 74.07%, P = 0.02). Prolonged stoma duration [HR = 0.991 (0.982– 1.000), P = 0.048] was an OS protective factor. Stoma reversal after chemotherapy [HR = 0.370 (0.141– 0.972), P = 0.044] and cumulative 5-FU dosage [HR = 0.991 (0.985– 0.997), P = 0.003] were DFS protective factors.Conclusion: In high-risk stage III patients, delayed stoma reversal after adjuvant chemotherapy may improve survival, but it may also lead to more stoma-related complications.Keywords: rectal cancer, protective ileostomy, adjuvant chemotherapy, survival, stoma-related complications
format Article
id doaj-art-4b3253a42bfe4a3f8b336098f511bcbc
institution DOAJ
issn 1179-1322
language English
publishDate 2025-04-01
publisher Dove Medical Press
record_format Article
series Cancer Management and Research
spelling doaj-art-4b3253a42bfe4a3f8b336098f511bcbc2025-08-20T03:10:39ZengDove Medical PressCancer Management and Research1179-13222025-04-01Volume 17801814102100Impact of the Timing of Protective Stoma Reversal on Survival in Rectal Cancer Patients Undergoing Postoperative Adjuvant Chemotherapy: A Retrospective Single Center StudyWang JLu XXu YWu YZhang TLi JJiwei Wang,&ast; Xiaoyun Lu,&ast; Yanan Xu, Yin Wu, Tao Zhang, Jianguo Li Department of General Surgery, Digestive Disease Hospital, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Jianguo Li, Department of General Surgery, Digestive Disease Hospital, Affiliated Hospital of Zunyi Medical University, 149 Dalian Road, Huichuan District, Zunyi, Guizhou, People’s Republic of China, Tel +86-13017410630, Email jianguo_zmu@163.comBackground: Postoperative adjuvant chemotherapy used in patients with stage II/III rectal cancer, is usually administered for 3 to 6 months. However, the optimal timing of protective stoma reversal remains controversial. This study aimed to investigate the effect of stoma closure before or after adjuvant chemotherapy on survival and stoma-related complications.Methods: A retrospective analysis was conducted on 144 patients who underwent radical rectal cancer surgery, prophylactic ileostomy and adjuvant chemotherapy from June 2018 to June 2021. 104 had their stoma reversal before adjuvant chemotherapy completion (Before group) and 40 after adjuvant chemotherapy completion (After group).Results: There were no significant differences between the groups regarding demographics, clinical characteristics, perioperative complications, OS, or DFS. Pathologic T-stage [HR = 2.620 (1.291– 5.320), P = 0.008 vs HR = 2.793 (1.297– 6.017), P = 0.009] and N-stage [HR = 2.204 (1.168– 4.157), P = 0.015 vs HR = 2.068 (1.125– 3.789), P = 0.019] were identified as independent risk factors for OS and DFS. Stoma reversal after completing chemotherapy [OR = 39.979 (3.964– 403.188), P = 0.002] and comorbidity [OR = 33.395 (5.931– 188.033), P < 0.001] were independent risk factors for stoma-related complications. In high-risk stage III patients with T4 or N2, the 3-year OS rate was significantly lower in Before group than in After group (70.3% vs 92.6%, P = 0.01), as was the 3-year DFS rate (60.94% vs 74.07%, P = 0.02). Prolonged stoma duration [HR = 0.991 (0.982– 1.000), P = 0.048] was an OS protective factor. Stoma reversal after chemotherapy [HR = 0.370 (0.141– 0.972), P = 0.044] and cumulative 5-FU dosage [HR = 0.991 (0.985– 0.997), P = 0.003] were DFS protective factors.Conclusion: In high-risk stage III patients, delayed stoma reversal after adjuvant chemotherapy may improve survival, but it may also lead to more stoma-related complications.Keywords: rectal cancer, protective ileostomy, adjuvant chemotherapy, survival, stoma-related complicationshttps://www.dovepress.com/impact-of-the-timing-of-protective-stoma-reversal-on-survival-in-recta-peer-reviewed-fulltext-article-CMARrectal cancerprotective ileostomyadjuvant chemotherapysurvivalstoma-related complications
spellingShingle Wang J
Lu X
Xu Y
Wu Y
Zhang T
Li J
Impact of the Timing of Protective Stoma Reversal on Survival in Rectal Cancer Patients Undergoing Postoperative Adjuvant Chemotherapy: A Retrospective Single Center Study
Cancer Management and Research
rectal cancer
protective ileostomy
adjuvant chemotherapy
survival
stoma-related complications
title Impact of the Timing of Protective Stoma Reversal on Survival in Rectal Cancer Patients Undergoing Postoperative Adjuvant Chemotherapy: A Retrospective Single Center Study
title_full Impact of the Timing of Protective Stoma Reversal on Survival in Rectal Cancer Patients Undergoing Postoperative Adjuvant Chemotherapy: A Retrospective Single Center Study
title_fullStr Impact of the Timing of Protective Stoma Reversal on Survival in Rectal Cancer Patients Undergoing Postoperative Adjuvant Chemotherapy: A Retrospective Single Center Study
title_full_unstemmed Impact of the Timing of Protective Stoma Reversal on Survival in Rectal Cancer Patients Undergoing Postoperative Adjuvant Chemotherapy: A Retrospective Single Center Study
title_short Impact of the Timing of Protective Stoma Reversal on Survival in Rectal Cancer Patients Undergoing Postoperative Adjuvant Chemotherapy: A Retrospective Single Center Study
title_sort impact of the timing of protective stoma reversal on survival in rectal cancer patients undergoing postoperative adjuvant chemotherapy a retrospective single center study
topic rectal cancer
protective ileostomy
adjuvant chemotherapy
survival
stoma-related complications
url https://www.dovepress.com/impact-of-the-timing-of-protective-stoma-reversal-on-survival-in-recta-peer-reviewed-fulltext-article-CMAR
work_keys_str_mv AT wangj impactofthetimingofprotectivestomareversalonsurvivalinrectalcancerpatientsundergoingpostoperativeadjuvantchemotherapyaretrospectivesinglecenterstudy
AT lux impactofthetimingofprotectivestomareversalonsurvivalinrectalcancerpatientsundergoingpostoperativeadjuvantchemotherapyaretrospectivesinglecenterstudy
AT xuy impactofthetimingofprotectivestomareversalonsurvivalinrectalcancerpatientsundergoingpostoperativeadjuvantchemotherapyaretrospectivesinglecenterstudy
AT wuy impactofthetimingofprotectivestomareversalonsurvivalinrectalcancerpatientsundergoingpostoperativeadjuvantchemotherapyaretrospectivesinglecenterstudy
AT zhangt impactofthetimingofprotectivestomareversalonsurvivalinrectalcancerpatientsundergoingpostoperativeadjuvantchemotherapyaretrospectivesinglecenterstudy
AT lij impactofthetimingofprotectivestomareversalonsurvivalinrectalcancerpatientsundergoingpostoperativeadjuvantchemotherapyaretrospectivesinglecenterstudy